TY - JOUR
T1 - Transitioning From Immunosuppressants to Dupilumab in Pediatric Atopic Dermatitis
AU - Ludwig, Catherine M.
AU - Hsiao, Jennifer L.
AU - Lio, Peter A.
AU - Shi, Vivian Y.
N1 - Publisher Copyright:
© Lippincott Williams & Wilkins.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - Dupilumab has recently been approved by the Food and Drug Administration for use for treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years. It presents a novel treatment option with a favorable safety profile for patients who are currently reliant on immunosuppressants, including cyclosporine A, methotrexate, and mycophenolate mofetil. Particularly during the current COVID-19 pandemic, immunosuppression should be avoided to retain intrinsic antiviral immunity. Transitioning to dupilumab should be executed strategically - tapering immunosuppressants and minimizing risk of flare by overlapping with the biologic. Herein, we use results of outcome measurements from LIBERTY AD ADOL and LIBERTY AD PEDS trials of dupilumab in adolescents aged 12 to 18 years and children aged 6 to 11 years, respectively, to propose a schematic for an 8-week transition between medications.
AB - Dupilumab has recently been approved by the Food and Drug Administration for use for treatment of moderate to severe atopic dermatitis in children aged 6 to 11 years. It presents a novel treatment option with a favorable safety profile for patients who are currently reliant on immunosuppressants, including cyclosporine A, methotrexate, and mycophenolate mofetil. Particularly during the current COVID-19 pandemic, immunosuppression should be avoided to retain intrinsic antiviral immunity. Transitioning to dupilumab should be executed strategically - tapering immunosuppressants and minimizing risk of flare by overlapping with the biologic. Herein, we use results of outcome measurements from LIBERTY AD ADOL and LIBERTY AD PEDS trials of dupilumab in adolescents aged 12 to 18 years and children aged 6 to 11 years, respectively, to propose a schematic for an 8-week transition between medications.
UR - http://www.scopus.com/inward/record.url?scp=85114809674&partnerID=8YFLogxK
U2 - 10.1097/DER.0000000000000690
DO - 10.1097/DER.0000000000000690
M3 - Review article
C2 - 33273236
AN - SCOPUS:85114809674
SN - 1710-3568
VL - 32
SP - S4-S7
JO - Dermatitis
JF - Dermatitis
IS - 1
ER -